Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. It is characterized by a wide spectrum of hepatic changes, which may progress to non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFLD is considered a hepatic manifestation of metabolic syndrome; however, mechanisms underlying the onset and progression of NAFLD are still unclear. Resident and recruited macrophages are key players in the homeostatic function of the liver and in the progression of NAFLD to NASH. Progress has been made in understanding the molecular mechanisms underlying the polarized activation of macrophages. New NAFLD therapies will likely involve modification of macrophage polarization by restraining M1 activation or driving M2 activation. Carotenoids are potent antioxidants and anti-inflammatory micronutrients that have been used to prevent and treat NAFLD. In addition to their antioxidative action, carotenoids can regulate macrophage polarization and thereby halt the progression of NASH. In this review, we summarize the molecular mechanisms of macrophage polarization and the function of liver macrophages/Kupffer cells in NAFLD. From our review, we propose that dietary carotenoids, such as β-cryptoxanthin and astaxanthin, be used to prevent or treat NAFLD through the regulation of macrophage polarization and liver homeostasis.

Keywords: NAFLD/NASH; carotenoids; macrophages/Kupffer cells; insulin resistance; inflammation; fibrosis; antioxidant; β-cryptoxanthin; astaxanthin

1. Introduction

Non-alcoholic fatty liver disease (NAFLD) is becoming increasingly prevalent. It is a common cause of chronic liver disease and a major indicator of metabolic syndrome [1]. Non-alcoholic steatohepatitis (NASH) is a more severe form of NAFLD that is broadly defined by the presence of steatosis with inflammation and progressive fibrosis [2], ultimately leading to cirrhosis and hepatocellular carcinoma (HCC) [3–5]. Multiple risk factors are associated with NAFLD, but the mechanisms underlying its onset and progression are still unclear. According to the initial “two-hit hypothesis”, insulin resistance is the “first hit” that leads to hepatic steatosis. The “second hit” is driven by oxidative stress, which leads to steatohepatitis and fibrosis [6]. In our previous studies, we found that insulin resistance promoted the progression of NASH from simple fatty liver [7]. Moreover, this traditional view has been developed within a more complex “multiple parallel-hit hypothesis”, which comprises a wide spectrum of parallel hits (Figure 1), including insulin resistance, oxidative stress, genetic and epigenetic mechanisms, environmental elements, cytokines, and microbiota changes [8].
Many cross-sectional clinical studies have been performed to elucidate the pathogenesis of NASH. However, due to the limitations of clinical studies, many researchers have focused on establishing animal models to assess the effect of different molecules on fatty liver formation. Dietary models of NASH are useful to mimic the pathogenesis of diet-induced obesity and its resulting metabolic disturbances, including NAFLD and NASH [9]. However, dietary methionine- and choline-deficient (MCD) mouse models experience severe weight loss and liver atrophy, which are not characteristics of NASH in human patients [10]. Similarly, a choline-deficient l-amino-acid (CDAA) diet causes weight loss and prevents insulin resistance [10]. Exclusive, long-term intake of a high-fat (HF) diet resulted in fatty liver and obesity in mice, but a HF diet over several months did not affect fibrosis [11]. Moreover, addition of trans fats or high levels of fat to a fructose diet promoted glucose and insulin insensitivity and fatty liver formation without fibrosis [12]. In our previous study, we found that a diet high in fat, cholesterol, and cholate led to the development of pathophysiological NASH in humans [13]. Furthermore, we found that excessive hepatic lipid accumulation promoted the activation of macrophages/Kupffer cells (KCs), leading to exacerbation of insulin resistance, hepatic inflammation and fibrogenesis [13].

Many pharmacotherapeutic strategies have been attempted in NASH, but there is no consensus on how to evaluate NASH patients or treat them using pharmacological therapies [14–16]. Recent randomized controlled trials have shown that insulin sensitizers, such as metformin or thiazolidinedione, do not improve liver histology significantly in NASH [17,18]. In the TONIC trial, both metformin and vitamin E did not lead to a sustained reduction in alanine aminotransferase (ALT) levels in children and adolescents with NAFLD. Although NASH resolution was greater in vitamin E-treated subjects, fibrosis was not improved [18]. In the PIVENS trial, pioglitazone improved
steatosis and inflammation but led to significant weight gain. In contrast, compared with placebo, vitamin E improved liver enzyme levels and all histological features of NASH, except fibrosis [17]. Therefore, there is a clear need for additional therapies. So far, it remains unclear whether micronutrient antioxidant supplementation, particularly carotenoids, can be used to prevent and treat NAFLD.

Efforts have been made to understand the roles of immune cells, such as macrophages, natural killer cells, Th1/Th2 cells and T regulatory cells (T regs), in the pathogenesis of NASH and their potential therapeutic relevance. Specifically, hepatic macrophages, which consist of resident KCs and recruited bone marrow-derived macrophages, are the major cells that produce inflammatory mediators, such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β, causing systemic insulin resistance and, ultimately, NASH [19]. In tissues, macrophages mature and acquire specialized functional phenotypes upon activation by different stimuli. In general, classical M1 activation is stimulated by Toll-like receptor (TLR) ligands, such as lipopolysaccharide (LPS) and interferon-gamma (IFN-γ), while alternative M2 activation is stimulated by IL-4/IL-13 [20,21]. Dysregulation and polarization of M1/M2 macrophages can lead to chronic inflammation, infection, cancer, obesity and its associated disorders, and NAFLD [21]. Recently, the protective effects of M2 macrophages/KCs were reported against alcoholic fatty liver disease and NAFLD by promoting M1 macrophage/KC apoptosis were reported [22]. Therefore, specific macrophage-targeted therapies are now starting to appear in the clinical arena. In particular, the reorienting and reshaping of macrophage polarization is extremely important in macrophage therapeutic targeting [23]. In this review, we discuss the involvement of hepatic macrophages/KCs on the pathogenesis of NASH and the impact of carotenoids on NAFLD prevention and treatment.

2. Micronutrients and NAFLD/NASH Management

The treatment of NAFLD patients should be based on a global approach, not only addressing insulin resistance and metabolic syndrome, but also including strategies focused on reducing oxidative stress, dyslipidemia, and cardiovascular risk. Apart from pharmacological therapies, the usual management of NAFLD includes lifestyle counseling to increase physical activity and achieve gradual weight reduction. Management of weight and overall fitness is the cornerstone of treatment for all patients with NAFLD. Several studies have demonstrated the benefit of weight loss in reducing steatosis or the NAFLD activity score on histology, with greater weight loss associated with more substantial improvements [24]. Reductions in ALT levels and steatosis occur even with small decreases in weight, whereas resolution of NASH, or even fibrosis, occurs with more marked or sustained weight loss, such as that observed after bariatric surgery [24–27]. However, weight loss through energy restriction is difficult to achieve and sustain [28]. Physical activity and exercise are also effective at decreasing steatosis. Cross-sectional and prospective studies have shown that physical activity decreases intrahepatic lipid levels [29]. Both aerobic and resistance exercises have been shown to improve liver function, independently of weight loss [30,31].

In addition to total energy intake, the composition of the diet also affects metabolic and endocrine functions, and overall energy balance in NAFLD patients [32]. General recommendations include reductions in the intake of total fat, saturated fatty acids, trans fatty acids, and fructose [33]. Most recommendations encourage the consumption of diets rich in fruits and vegetables for prevention of chronic disease, including NAFLD. Such diets would provide a significant amount of bioactive components with known beneficial effects, in part, to their anti-inflammatory and anti-oxidative properties [32,33]. Therefore, these bioactive compounds or micronutrients, taken in combination with conventional treatments for cardio-metabolic diseases, may be used to prevent and treat NAFLD.

Several nutraceutical supplements have shown promising results as NAFLD treatments, especially those containing antioxidants and polyphenols, such as omega-3 fatty acids [34,35], anthocyanins, silymarin, and resveratrol [36]. However, results are derived mostly from animal studies and small trials with considerable heterogeneity with respect to inclusion criteria, sample size, type of experimental interventions and duration. Therefore, there are insufficient data to support or refute
the use of these bioactive compounds to treat NAFLD patients. Further studies, especially large-scale, well-designed, randomized controlled trials, should be performed to verify the therapeutic effect of these compounds on NAFLD.

3. Liver Macrophages in NAFLD/NASH

Macrophages are an essential component of innate immunity and play a central role in inflammation and host defense [37]. Tissue-resident and -recruited macrophages are major players in the mechanisms of innate resistance and are links between inflammation and cancer [21,38]. In the liver, resident macrophages/KCs fulfill homeostatic functions, orchestrate tissue remodeling in ontogenesis, and regulate metabolic functions. KCs are strategically positioned in liver sinusoids, where they trap and phagocytose microbes in the circulation and act as the first line of resistance against blood-borne pathogens [21,38]. In addition, KCs have been found to interact with other immune cells involved in the pathogenesis of NAFLD [39]. Under steady-state conditions, KCs can inhibit dendritic cell-induced antigen-specific T cell activation and promote the suppressive activity of T regs. Upon activation by bacterial antigens, such as LPS, KCs modulate the differentiation and activation of various immune cells, including dendritic cells, T lymphocytes and neutrophils [40]. Resident and recruited cells of the monocyte-macrophage lineage exert a dual function in liver pathology [41,42]. Moreover, KC identification is based on the expression of F4/80 and CD11b and/or CD68. Liver F4/80+CD68+ macrophages are characteristic of resident KCs, which are phagocytic cells that produce reactive oxygen species. Cytokine-producing bone marrow-derived macrophages (BMDMs) express CD11b+ [43]. Compared with CD11b+ cells, CD68+ cells preferentially adhere to liver sinusoidal endothelial cells or hepatocytes [44,45].

Cells of the monocyte-macrophage lineage are characterized by considerable diversity and plasticity. In tissues, mononuclear phagocytes respond to environmental cues (e.g., microbial products, damaged cells and activated lymphocytes) with the acquisition of distinct functional phenotypes. In response to various signals, macrophages may undergo classical M1 activation (stimulated by TLR ligands and IFN-γ) or alternative M2 activation (stimulated by IL-4/IL-13) [46]. Plasticity and flexibility are key features of mononuclear phagocytes and of their activated states [21,38]. The phenotype of polarized M1/M2 macrophages can, to some extent, be reversed in vitro and in vivo [21,38]. Moreover, pathology is frequently associated with dynamic changes in macrophage activation, with classically-activated M1 cells implicated in initiating and sustaining inflammation, and M2 or M2-like cells associated with decreasing chronic inflammation [47].

3.1. Molecular Determinants of Macrophage Polarization

A network of signaling molecules, transcription factors, epigenetic mechanisms, and post-transcriptional regulators underlie the different forms of macrophage activation (Figure 2). Macrophage polarization is regulated by the interferon regulatory factor (IRF)/signal transducer and activator of transcription (STAT)/suppressor of cytokine signaling (SOCS) (IRF-STAT-SOCS) family of proteins. Canonical IRF/STAT signaling activation by IFN and TLR signaling induces a M1 macrophage phenotype through STAT1, and IL-4 and IL-13 signaling induces a M2 macrophage phenotype via STAT6 [21,48]. M1 macrophages upregulate IRF5, which is essential for the induction of cytokines (IL-12, IL-23 and TNF-α) involved in eliciting Th1 and Th17 responses [49]. The IL-4 type I and type II receptors activate Stat6 [37], which in turn activate the transcription of genes associated with M2 polarization including mannose receptor (Mrc1), resistin-like α (Retnla), and chitinase 3-like 3 (Chi3l3) [50]. IL-10 activates STAT3-mediated expression of genes (Il10, Tgfb1 and Mrc1) associated with a M2-like phenotype [51,52]. It has been suggested that IL-3-mediated STAT5 activation promotes M2 polarization [38]. IRF5 and IRF8 regulation through Notch are also part of the M1-associated transcriptional network [49,53].
Members of the SOCS family regulate STAT-mediated activation of macrophages. LPS or IFN-γ concert with TLR stimulation to upregulate SOCS1 and SOCS3 expression which, in turn, inhibit the activation of STAT1 and STAT3, respectively. On the other hand, upregulation of SOCS1 is crucial for IL-4-induced M2 characteristics [54,55]. A recent study showed that Notch signaling plays a critical role in the determination of M1 versus M2 polarization of macrophages, and compromised Notch pathway activation leads to a M2-like phenotype [56]. Furthermore, it was found that this effect is regulated in a SOCS3-dependent manner [56].

Additionally, downstream transcription factors also contribute to macrophage polarization. The nuclear receptors peroxisome proliferator activated receptor (PPAR)γ and PPARδ control a distinct subset of genes associated with M2 macrophage activation and oxidative metabolism [19,57,58]. Interestingly, Krüppel-like factor 4 (KLF4) cooperates with Stat6 to promote M2 gene transcription (Arg-1, Mrc1, Fizz1, and PPARγ) and inhibit M1 gene transcription (Tnf-α, Cox-2, Ccl (C-C chemokine ligand) 5, and iNOS) via sequestration of coactivators required for nuclear factor kappa-light-chain-enhancer of activated B cells’ (NF-κB) activation [59]. KLF2 regulates macrophage activation by inhibiting NF-κB/hypoxia-inducible factor (HIF)-1α activity [60]. IL-4 also induces c-Myc activity in human macrophages, which controls genes involved in M2 (Scarb1, Alox15, and Mrc1), STAT6, and PPARγ activation [61]. TLR-mediated NF-κB activation can produce inflammatory mediators associated with M1 macrophages, but can also activate genetic programs essential for the resolution of inflammation and M2 polarization [62]. In addition, c-Jun N-terminal kinase (JNK) activation is required for M1 polarization of macrophages during obesity-induced inflammation and insulin resistance [63]. Other factors such as HIF-1α and HIF-2α are expressed differentially in M1 and M2 macrophages and regulate inducible NOS2 and arginase 1 expression, respectively [64].
More recently, microRNAs (miRNAs) have emerged as critical regulators of macrophage polarization. In particular, TLR signaling triggers the expression of a different set of miRNAs that regulate key molecules involved in macrophage polarization and affect the balance of pro- and anti-inflammatory responses [65]. miR-127-3p, miR-155-5p, miR-181a, miR-204-5p, and miR-451 were significantly upregulated in the presence of LPS and IFN-γ in murine BMDMs, while miR-125-5p, miR-143-3p, miR-145-5p, and miR-146a-3p were downregulated in M2-polarized BMDMs [47]. Moreover, miR-27a, miR-29b, miR-125a, miR-146a, and miR-155 were remarkably upregulated in polarized M1 macrophages, whereas miR-26a and miR-193b were upregulated in polarized M2 macrophages [66]. Therefore, the identification of specific miRNAs related to changes in macrophage polarization will increase our understanding of the molecular basis of disease progression and lead to the development of novel miRNA-targeted therapies.

3.2. Function of Liver Macrophages in NAFLD/NASH

Upon recognition of a foreign substance, KCs are activated and release a variety of inflammatory mediators, including cytokines (e.g., TNF-α, IL-1β, and IL-6), chemokines (monocyte chemotactic protein 1 (MCP-1)), macrophage inflammatory protein (MIP)-1α, MIP-1β, and RANTES [67]. All of these mediators may cause hepatic toxicity and liver function impairment. These factors regulate the phenotype of KCs as well as that of neighboring cells, such as hepatocytes, hepatic stellate cells (HSCs), liver sinusoidal endothelial cells, and other immune cells that traffic through the liver [41]. In parallel, cytokines and chemokines, which are secreted by KCs, lead to the recruitment of neutrophils, natural killer T lymphocytes, natural killer cells, and blood monocyte-derived macrophages to the liver [68,69].

KCs are involved in the control of inflammatory responses in NAFLD. During the early stages of the disease, hepatic macrophages expand rapidly and secrete cytokines and chemokines, such as IL-1β, TNF-α, MCP-1, and CCL5, contributing to paracrine activation of protective or apoptotic signaling pathways in hepatocytes, and the recruitment of other immune cells [70]. Moreover, these inflammatory mediators can lead to tissue damage in ischemia reperfusion, endotoxemia, acetaminophen-induced liver hepatotoxicity, and alcohol-induced liver steatosis [71,72]. KCs may also express immunoregulatory molecules, such as IL-10, and transforming growth factor beta (TGF-β). An unbalanced production of pro- and anti-inflammatory mediators by KCs can lead to liver injury [38,73].

Although hepatic insulin resistance is involved in the progression of NAFLD, multiple cytokines have been implicated in the pathogenesis of hepatic insulin resistance [43]. Obesity-induced KCs activation leads to the production of pro-inflammatory cytokines, which inhibit hepatocyte insulin signaling through a paracrine mechanism [74,75]. By regulating the oxidation of fatty acids, KCs increase lipid storage in hepatocytes during obesity, which results in hepatic insulin resistance [76]. This effect is triggered by inflammatory cytokines, such as TNFα, IL-6, and IL-1β [76]. Moreover, under certain conditions, alternative activation of KCs by IL-4/IL-13 has been found to ameliorate obesity-induced insulin resistance by regulating PPARδ [19,69], suggesting a beneficial role for M2-activated KCs in metabolic syndrome and NAFLD.

Fibrosis is a key feature of chronic liver inflammation and NASH, and activated macrophages exert a dual function in the orchestration of matrix deposition and remodeling [77,78]. HSCs, in response to damage, differentiate into myofibroblast-like cells, which produce extracellular matrix (ECM) components in pathology. HSCs and their progeny engage in bidirectional interaction with resident and recruited macrophages [79]. Depending on the context and specific activation signals, macrophages can exert dual functions on HSCs and ECM deposition [38]. Phagocytosis of dying necrotic cells and debris triggers the production of TGF-β by KCs and recruited macrophages [80,81]. On the other hand, phagocytosis of apoptotic hepatocytes and cholangiocytes has been shown to dampen the development of fibrosis [82]. IL-13 signaling, which polarize M2 macrophages, induces the production of TGF-β and its activation by matrix metalloproteinase-9 [83]. Moreover, monocytes/macrophages expressing chemokine receptors, such as C-C chemokine receptor (CCR)2, CCR1, and CCR5, are thought to interact with HSCs through TGF-β to promote fibrosis [84,85].
4. Carotenoids and NAFLD/NASH

Due to increasing prevalence and incidence, and a lack of established therapeutic interventions, NAFLD has emerged as one of the most important health problems worldwide. Therefore, increasing numbers of studies have focused on natural dietary compounds for the prevention and treatment of NAFLD. Antioxidant micronutrients, such as vitamins and carotenoids, exist in abundance in fruits and vegetables and defend against reactive oxygen species [86]. Carotenoids accumulate mainly in the liver and incorporate into lipoproteins for release into the circulation [87]. Ingested carotenoids may participate in an antioxidant defense system when free radical species in the liver are present at high concentrations, and these physiological functions of carotenoids could inhibit the development of liver dysfunction [88]. On the other hand, micronutrient antioxidants are severely depleted in the serum and liver tissue of patients with chronic liver diseases [89], and liver injury is associated with decreased antioxidant levels, particularly carotenoids [90]. Thus, micronutrient antioxidant deficiencies may contribute to the development of obesity and comorbidities, such as insulin resistance and NASH [91,92]. Recently, low serum concentrations of carotenoids, such as \( \alpha \)-carotene, \( \beta \)-carotene and vitamin E, were shown to be associated with obesity [90,91,93]. Moreover, greater serum carotenoid levels are associated with lower serum ALT levels and a lower risk of developing NAFLD [94,95]. There is growing evidence for the use of vitamin E in the treatment of NASH [96]. Dietary \( \alpha \)-tocopherol supplementation was recently found to attenuate LPS levels, and a MCD diet induced oxidative stress and inflammation-related responses in NASH in mice [97,98]. Importantly, carotenoids were found to be as potent as vitamin E in inhibiting lipid peroxidation [99]. However, carotenoid supplementation (\( \beta \)-cryptoxanthin and astaxanthin) has not been widely used as an antioxidant therapy in NASH treatments. The mechanism of action of carotenoids, including \( \beta \)-cryptoxanthin and astaxanthin, in NAFLD is unclear, but there is evidence they may work through multiple mechanisms, including antioxidant and anti-inflammatory effects [88,100], and regulation of M1/M2 macrophage polarization [101,102].

4.1. \( \beta \)-Cryptoxanthin

\( \beta \)-Cryptoxanthin is a xanthophyll carotenoid specifically found in the Satsuma mandarin (\textit{Citrus unshiu} Marc.). \( \beta \)-Cryptoxanthin is readily absorbed and relatively abundant in human plasma, together with \( \alpha \)-carotene, \( \beta \)-carotene, lycopene, lutein, and zeaxanthin [103–105]. Similar to other carotenoids, \( \beta \)-cryptoxanthin has antioxidant activity [106,107] and higher bioavailability than those of \( \beta \)-carotene in rodents [87]. Serum \( \beta \)-cryptoxanthin concentrations were found to be inversely associated with indices of oxidative DNA damage and lipid peroxidation [108]. Recent epidemiological studies showed that serum \( \beta \)-cryptoxanthin levels were inversely associated with insulin resistance risk and alcohol-induced increases in serum \( \gamma \)-glutamyltransferase levels in nondiabetic subjects and alcohol drinkers, respectively [104,105]. In addition, \( \beta \)-cryptoxanthin suppressed LPS-induced osteoclast formation in co-cultures of bone marrow cells and osteoblasts, and restored alveolar bone loss induced by LPS in mice [109]. Moreover, \( \beta \)-cryptoxanthin can accumulate in RAW264.7 cells and induce changes in the intracellular redox status, in turn regulating the immune function of macrophages [110].

In our previous study, we found that \( \beta \)-cryptoxanthin prevented the development of NASH by attenuating fat accumulation, increases in KC numbers, activation of stellate cells, and fibrosis in mouse models of lipotoxicity-induced NASH [101,111]. Comprehensive gene expression studies have shown that \( \beta \)-cryptoxanthin is more effective in inhibiting the inflammatory gene expression changes that accompany NASH [111]. \( \beta \)-Cryptoxanthin downregulated the expression of genes associated with cell death, inflammatory responses, free radical scavenging, and infiltration and activation of macrophages, leukocytes, and T cells [111]. However, it showed little effect on the expression of genes related to the metabolism of cholesterol and other lipids [111]. Moreover, \( \beta \)-cryptoxanthin reversed pre-existing NASH in mice [101]. \( \beta \)-Cryptoxanthin inhibited lipid accumulation and peroxidation in the liver due to its strong anti-oxidative properties. Furthermore, \( \beta \)-cryptoxanthin reduced the accumulation of T cells and macrophages, and regulated the M1/M2 status of macrophages/KCs in the liver without affecting
the recruitment of monocytes from the bone marrow [101]. Additionally, β-cryptoxanthin directly decreased LPS-induced M1 activation and augmented IL-4-induced M2 macrophage activation in vitro, suggesting macrophages may be directly targeted by β-cryptoxanthin (Figure 3) [101]. Therefore, strategies that inhibit M1 polarization and/or drive alternative M2 macrophage/KC activation may protect against inflammation, thereby halting NASH progression.

4.2. Astaxanthin

Astaxanthin is another xanthophyll carotenoid found in various microorganisms and marine animals, including salmon, crabs, and crustaceans [112]. Astaxanthin is well known for its strong antioxidant capacity [113]. It is 100–500-fold more effective than vitamin E at preventing lipid peroxidation. It has hepatoprotective effects and can protect against inflammation, ulcers, cancer, neurodegeneration, diabetes, immune-system attacks, and cardiovascular disease [112,114]. Astaxanthin has been reported to inhibit carbon tetrachloride-induced lipid peroxidation and to increase glutathione (GSH) levels and superoxide dismutase (SOD) activity in rat liver [115]. Astaxanthin prevented diet-induced obesity and hepatic triglyceride accumulation and steatosis in mice [116,117]. Moreover, astaxanthin prevented and reversed the activation of mouse primary HSCs and suppressed the upregulation of fibrogenic genes by blocking TGF-β/Smad3 signaling [118,119]. In addition, astaxanthin ameliorated insulin resistance by protecting cells from oxidative stress [120]. Therefore, the use of astaxanthin as a nutritional supplement has increased significantly in recent years.

We recently compared the preventative and therapeutic effects of astaxanthin and vitamin E in a lipotoxic NASH mouse model [102]. We found that astaxanthin had significant preventative and therapeutic effects (Figure 3). Astaxanthin attenuated insulin resistance, hepatic lipid accumulation and peroxidation, stellate cell activation and fibrosis, and it decreased the proportion of proinflammatory or M1-type macrophages/KCs in diet-induced NASH. In addition, astaxanthin ameliorated simple

Figure 3. Schematic representation of the hepatoprotective effect of carotenoids on the progression of NAFLD/NASH. Carotenoids may improve NAFLD/NASH by inhibiting lipogenesis, β-oxidation of free fatty acids, inflammation, and HSC activation. In addition, apart from their common anti-oxidative and anti-inflammatory properties, carotenoids, such as β-cryptoxanthin and astaxanthan, can contribute to liver homeostasis by regulating the polarization of M1/M2 macrophages/KCs.
steatosis, the early stage of NAFLD, in both genetically (ob/ob) and diet-induced obese mice. Finally, we demonstrated that astaxanthin has the potential to improve NASH in humans [102].

The different mechanisms of action of astaxanthin and vitamin E in NASH mouse models are intriguing, because both of these lipophilic antioxidants suppress hepatic lipid peroxidation to an equivalent extent. Collectively, these results suggest that astaxanthin is more effective at preventing and treating NASH than is vitamin E [102]. First, astaxanthin was superior to vitamin E at improving steatosis by suppressing lipid accumulation. Second, astaxanthin reduced inflammation and insulin resistance more potently than did vitamin E. Of note, these anti-inflammatory and insulin-sensitizing effects were associated with attenuated MAPK (JNK/p38 MAPK) signaling and NF-κB activation, decreased macrophage/KC and T cell accumulation, and enhanced alternative M2 macrophage activation in the liver. Finally, astaxanthin prevented and reversed hepatic fibrosis to a greater extent than did vitamin E. Our in vitro study demonstrated that astaxanthin can act directly on hepatocytes by decreasing lipid accumulation, enhancing insulin signaling and suppressing inflammatory signaling. Additionally, astaxanthin administration decreased M1 macrophage marker activation and increased M2 macrophage marker activation in RAW264.7 macrophages, indicating macrophages are also a direct target of astaxanthin [102]. Therefore, astaxanthin confers its beneficial effects by regulating macrophage homeostasis and may be a potential candidate for the prevention or treatment of insulin resistance and NASH.

4.3. Other Carotenoids and NAFLD

Other carotenoids such as lycopene, and β-carotene have also been demonstrated to exert a protective effect in NAFLD. Lycopene, a non-provitamin A carotenoid, is found at high concentrations in red fruits and vegetables such as tomatoes, red grapefruit, watermelon, and apricots. Dietary supplementation with lycopene reduces the risk of cancers in many organs, and has chemopreventive effects against other diseases, including nonalcoholic steatohepatitis-promoted hepatocarcinogenesis [121]. Lycopene also reduces the development of hepatic steatosis induced by a HF diet [122]. Significantly reduced plasma lycopene levels were observed in NASH patients, suggesting a potential interaction between low lycopene status and the development of liver diseases [123].

β-Carotene is the most widely distributed carotenoid in yellow-orange and dark green fruits and vegetables. Studies have shown the potential preventive and therapeutic effects of β-carotene on hepatic inflammation, fibrosis, and cirrhosis [88]. Dietary β-carotene supplementation was found to have a protective effect on liver damage [88].

5. Conclusions

NAFLD has become one of the most important chronic liver diseases in the world. Its association with obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and progression to cirrhosis and HCC increases its clinical importance. NAFLD pathogenesis is very complex and may involve many mechanisms. A detailed understanding of the pathogenetic mechanisms is needed to develop new preventative and therapeutic strategies. Moreover, the treatment of NAFLD patients should be based on a global approach, and it should address not only insulin resistance and metabolic syndrome, but also strategies to reduce oxidative stress, dyslipidemia, and cardiovascular risk. Although insulin resistance and increased oxidative stress are believed to be major risk factors for the progression to NASH many agents, including insulin sensitizers, have been evaluated with disappointing results in the management of NASH. Carotenoids, which are natural antioxidant compounds possessing anti-inflammatory properties, appear to be beneficial in the prevention and treatment of NAFLD. Our recent studies provide evidence that dietary β-cryptoxanthin or astaxanthin can prevent and reverse the progression of NASH in mice. Other carotenoids, including lycopene and β-carotene, may also help improve NAFLD progression.
Macrophages play an important role in the pathogenesis of oxidative stress, insulin resistance, and NAFLD. Therefore, new therapies for the treatment of inflammation and insulin resistance may involve strategies that modify macrophage polarization by either restraining M1 activation or driving M2 activation. In addition to their common effects, carotenoids, such as β-cryptoxanthin and astaxanthin, may contribute to liver homeostasis by directly regulating macrophage polarization, thereby halting the progression of NASH. Future investigations are warranted to elucidate the precise mechanisms mediating the preventative and therapeutic effects of carotenoids in NAFLD.

Acknowledgments: This work was supported by the following grants: Grant-in-Aid for Young Scientists (B) (16K18700) (Y.N), Grant-in-Aid for Young Scientists (A) (15H05345) (M.N.), Grant-in-Aid for Scientific Research (B) (25282017, 16H03035) (T.O.), and Challenging Exploratory Research (15K12698) (T.O.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; and Research Project on Development of Agricultural Products and Foods with Health-Promoting Benefits (NARO) (2013-A-10) (T.O.) from the Ministry of Agriculture, Forestry and Fisheries (MAFF).

Author Contributions: All authors contributed to the preparation of this review and approved the text.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:

| Abbreviation | Description |
|--------------|-------------|
| NAFLD        | Non-alcoholic fatty liver disease |
| NASH         | Non-alcoholic steatohepatitis |
| HCC          | Hepatocellular carcinoma |
| KC           | Kupffer cell |
| HSC          | Hepatic stellate cell |
| TLR          | Toll-like receptor |
| LPS          | Lipopolysaccharide |
| IFN-γ        | Interferon-gamma |
| IRF          | Interferon Regulatory Factor |
| STAT         | Signal Transducer and Activator of Transcription |
| SOCS         | Suppressor of Cytokine Signaling |
| PPAR         | Peroxisome Proliferator Activated Receptor |
| KLF4         | Krüppel-Like Factor 4 |
| ECM          | Extracellular Matrix |
| CCL          | C-C chemokine ligand |
| CCR          | C-C chemokine receptor |

References

1. Pacifico, L.; Anania, C.; Martino, F.; Poggiogalle, E.; Chiarelli, F.; Arca, M.; Chiesa, C. Management of metabolic syndrome in children and adolescents. *Nutr. Metab. Cardiovasc. Dis.* **2011**, *21*, 455–466. [CrossRef] [PubMed]
2. Brunt, E.M.; Kleiner, D.E.; Wilson, L.A.; Unalp, A.; Behling, C.E.; Lavine, J.E.; Neuschwander-Tetri, B.A.; NASH Clinical Research Network. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced nafl-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. *Hepatology* **2009**, *49*, 809–820. [CrossRef] [PubMed]
3. Yatsuji, S.; Hashimoto, E.; Tobari, M.; Tanai, M.; Tokushige, K.; Shiratori, K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. *J. Gastroenterol. Hepatol.* **2009**, *24*, 248–254. [CrossRef] [PubMed]
4. Fassio, E.; Alvarez, E.; Dominguez, N.; Landeira, G.; Longo, C. Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies. *Hepatology* **2004**, *40*, 820–826. [CrossRef] [PubMed]
5. Ono, M.; Saibara, T. Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature. *J. Gastroenterol.* **2006**, *41*, 725–732. [CrossRef] [PubMed]
6. Day, C.P.; James, O.F. Steatohepatitis: A tale of two “hits”? *Gastroenterology* **1998**, *114*, 842–845. [CrossRef]
7. Ota, T.; Takamura, T.; Kurita, S.; Matsuzawa, N.; Kita, Y.; Uno, M.; Akahori, H.; Misu, H.; Sakurai, M.; Zen, Y.; et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. *Gastroenterology* **2007**, *132*, 282–293. [CrossRef] [PubMed]
8. Takaki, A.; Kawai, D.; Yamamoto, K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). *Int. J. Mol. Sci.* 2013, *14*, 20704–20728. [CrossRef] [PubMed]

9. Marchesini, G.; Brizi, M.; Bianchi, G.; Tomassetti, S.; Bugianesi, E.; Lenzi, M.; McCullough, A.J.; Natale, S.; Forlanì, G.; Melchionda, N. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. *Diabetes* 2001, *50*, 1844–1850. [CrossRef] [PubMed]

10. Hebbard, L.; George, J. Animal models of nonalcoholic fatty liver disease. *Nat. Rev. Gastroenterol. Hepatol.* 2011, *8*, 35–44. [CrossRef] [PubMed]

11. Matsumoto, M.; Hada, N.; Sakamaki, Y.; Uno, A.; Shiga, T.; Tanaka, C.; Ito, T.; Katsume, A.; Sudoh, M. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. *Int. J. Exp. Pathol.* 2013, *94*, 93–103. [CrossRef] [PubMed]

12. Wada, T.; Kenmochi, H.; Miyashita, Y.; Sasaki, M.; Ojima, M.; Sasahara, M.; Koya, D.; Tsunekì, H.; Sasaoka, T. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. *Endocrinology* 2010, *151*, 2040–2049. [CrossRef] [PubMed]

13. Matsuzawa, N.; Takamura, T.; Kurita, S.; Misu, H.; Ota, T.; Ando, H.; Yokoyama, M.; Honda, M.; Zen, Y.; Nakamura, Y.; et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. *Hepatology* 2007, *46*, 1392–1403. [CrossRef] [PubMed]

14. Younossi, Z.M. Review article: Current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Aliment. Pharmacol. Ther.* 2008, *28*, 2–12. [CrossRef] [PubMed]

15. Arab, J.P.; Candia, R.; Zapata, R.; Munoz, C.; Arancibia, J.P.; Poniachik, J.; Soza, A.; Fuster, F.; Brahm, J.; Sanhueza, E.; et al. Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. *World J. Gastroenterol.* 2014, *20*, 12182–12201. [CrossRef] [PubMed]

16. Musso, G.; Gambino, R.; Cassader, M.; Pagano, G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. *Hepatology* 2010, *52*, 79–104. [CrossRef] [PubMed]

17. Sanyal, A.J.; Chalasani, N.; Kowdley, K.V.; McCullough, A.; Diehl, A.M.; Bass, N.M.; Neuschwander-Tetri, B.A.; Lavine, J.E.; Tonascia, J.; Unalp, A.; et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N. Engl. J. Med.* 2010, *362*, 1675–1685. [CrossRef] [PubMed]

18. Lavine, J.E.; Schwimmer, J.B.; van Natta, M.L.; Molleston, J.P.; Murray, K.F.; Rosenthal, P.; Abrams, S.H.; Scheimann, A.O.; Sanyal, A.J.; Chalasani, N.; et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The tonic randomized controlled trial. *JAMA* 2011, *305*, 1659–1668. [CrossRef] [PubMed]

19. Odegaard, J.I.; Ricardo-Gonzalez, R.R.; Eagle, A.R.; Vats, D.; Morel, C.R.; Subramanian, V.; Mukundan, L.; Ferrante, A.W.; Chawla, A. Alternative M2 activation of Kupffer cells by ppardelta ameliorates obesity-induced insulin resistance. *Cell Metab.* 2008, *7*, 496–507. [CrossRef] [PubMed]

20. Martinez, F.O.; Gordon, S. The M1 and M2 paradigm of macrophage activation: Time for reassessment. *F1000Prime Rep.* 2014, *6*, 13. [CrossRef] [PubMed]

21. Sica, A.; Mantovani, A. Macrophage plasticity and polarization: In vivo veritas. *J. Clin. Investig.* 2012, *122*, 787–795. [CrossRef] [PubMed]

22. Wan, J.; Benkdane, M.; Teixeira-Clerc, F; Bonnafous, S.; Louvet, A.; Lafdíl, F.; Pecker, F.; Tran, A.; Gual, P.; Mallat, A.; et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: A protective mechanism against alcoholic and nonalcoholic fatty liver disease. *Hepatology* 2014, *59*, 130–142. [CrossRef] [PubMed]

23. Xue, J.; Sharma, V.; Hsieh, M.H.; Chawla, A.; Murali, R.; Pandol, S.J.; Habtezion, A. Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis. *Nat. Commun.* 2015, *6*, 7158. [CrossRef] [PubMed]

24. Rinella, M.E.; Sanyal, A.J. Management of NAFLD: A stage-based approach. *Nat. Rev. Gastroenterol. Hepatol.* 2016, *13*, 196–205. [CrossRef] [PubMed]

25. Wong, V.W.; Chan, R.S.; Wong, G.L.; Cheung, B.H.; Chu, W.C.; Yeung, D.K.; Chim, A.M.; Lai, J.W.; Li, L.S.; Sea, M.M.; et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial. *J. Hepatol.* 2013, *59*, 536–542. [CrossRef] [PubMed]

26. Promrat, K.; Kleiner, D.E.; Niemeier, H.M.; Jackvony, E.; Kearns, M.; Wands, J.R.; Fava, J.L.; Wing, R.R. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 2010, *51*, 121–129. [CrossRef] [PubMed]
27. Lassailly, G.; Caiazzo, R.; Buob, D.; Pigeyre, M.; Verkindt, H.; Labreuche, J.; Raverdy, V.; Leteurtre, E.; Dharny, S.; Louvet, A.; et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. *Gastroenterology* 2015, **149**, 379–388. [CrossRef] [PubMed]

28. Centis, E.; Moscatiello, S.; Bugianesi, E.; Bellentani, S.; Fracanzani, A.L.; Calugi, S.; Petta, S.; Dalle Grave, R.; Marchesini, G. Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. *J. Hepatol.* 2013, **58**, 771–777. [CrossRef] [PubMed]

29. St George, A.; Bauman, A.; Johnston, A.; Farrell, G.; Chey, T.; George, J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. *Hepatology* 2009, **50**, 68–76. [CrossRef] [PubMed]

30. Johnson, N.A.; Sachinwalla, T.; Walton, D.W.; Smith, K.; Armstrong, A.; Thompson, M.W.; George, J. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. *Hepatology* 2009, **50**, 1105–1112. [CrossRef] [PubMed]

31. Hallsworth, K.; Fattakhova, G.; Hollingsworth, K.G.; Thoma, C.; Moore, S.; Taylor, R.; Day, C.P.; Trenell, M.I. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. *Gut* 2011, **60**, 1278–1283. [CrossRef] [PubMed]

32. Musso, G.; Gambino, R.; de Michieli, F.; Cassader, M.; Rizzetto, M.; Pagano, G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. *Hepatology* 2003, **37**, 909–916. [CrossRef] [PubMed]

33. Dongiovanni, P.; Lanti, C.; Riso, P.; Valenti, L. Nutritional therapy for nonalcoholic fatty liver disease. *J. Nutr. Biochem.* 2016, **29**, 1–11. [CrossRef] [PubMed]

34. Zhu, F.S.; Liu, S.; Chen, X.M.; Huang, Z.G.; Zhang, D.W. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. *World J. Gastroenterol.* 2008, **14**, 6395–6400. [CrossRef] [PubMed]

35. Parker, H.M.; Johnson, N.A.; Burdon, C.A.; Cohn, J.S.; O'Connor, H.T.; George, J. Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. *J. Hepatol.* 2012, **56**, 944–951. [CrossRef]

36. Del Ben, M.; Polimeni, L.; Baratta, F.; Pastori, D.; Angelico, F. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. *Br. J. Clin. Pharmacol.* 2016. [CrossRef] [PubMed]

37. Gordon, S.; Martinez, F.O. Alternative activation of macrophages: Mechanism and functions. *Immunity* 2010, **32**, 593–604. [CrossRef] [PubMed]

38. Sica, A.; Invernizzi, P.; Mantovani, A. Macrophage plasticity and polarization in liver homeostasis and pathology. *Hepatology* 2008, **49**, 2034–2042. [CrossRef] [PubMed]

39. Crispe, I.N. Hepatic t cells and liver tolerance. *Nat. Immunol.* 2014, 4077–4085. [PubMed]

40. Vonghia, L.; Michielsen, P.; Francque, S. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. *Int. J. Mol. Sci.* 2013, **14**, 19867–19890. [CrossRef] [PubMed]

41. Duffield, J.S.; Forbes, S.J.; Constandinou, C.M.; Clay, S.; Partolima, M.; Vuthoori, S.; Wu, S.; Lang, R.; Iredale, J.P. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. *J. Clin. Invest.* 2005, **115**, 56–65. [PubMed]

42. Liaskou, E.; Zimmermann, H.W.; Li, K.K.; Oo, Y.H.; Suresh, S.; Tramunti, S.; Qureshi, O.; Lalar, P.F.; Shaw, J.; Syn, W.K.; et al. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. *Hepatology* 2013, **57**, 385–398. [PubMed]

43. Jager, J.; Aparicio-Vergara, M.; Aouadi, M. Liver innate immune cells and insulin resistance: The multiple facets of Kupffer cells. *J. Intern. Med.* 2016. [CrossRef] [PubMed]

44. Ikarashi, M.; Nakashima, H.; Kinoshita, M.; Sato, A.; Nakashima, M.; Miyazaki, H.; Nishiya, K.; Yamamoto, J.; Seki, S. Distinct development and functions of resident and recruited liver Kupffer cells/macrophages. *J. Leukoc. Biol.* 2013, **94**, 1325–1336. [PubMed]

45. Klein, I.; Cornejo, J.C.; Polakos, N.K.; John, B.; Wuensh, S.A.; Topham, D.J.; Pierce, R.H.; Crispe, I.N. Kupffer cell heterogeneity: Functional properties of bone marrow derived and sessile hepatic macrophages. *Blood* 2007, **110**, 4077–4085. [PubMed]

46. Biswas, S.K.; Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. *Nat. Immunol.* 2010, **11**, 889–896. [PubMed]

47. Zhang, Y.; Zhang, M.; Zhong, M.; Sui, Q.; Lv, K. Expression profiles of mirnas in polarized macrophages. *Int. J. Mol. Med.* 2013, **31**, 797–802. [PubMed]
48. Sica, A.; Bronte, V. Altered macrophage differentiation and immune dysfunction in tumor development. 
    *J. Clin. Investig.* **2007**, *117*, 1155–1166. [CrossRef] [PubMed]

49. Krausgruber, T.; Blazek, K.; Smallic, T.; Alzabin, S.; Lockstone, H.; Sahgal, N.; Hussell, T.; Feldmann, M.; 
    Udalova, I.A. IRF5 promotes inflammatory macrophage polarization and TH1–TH17 responses. 
    *Nat. Immunol.* **2011**, *12*, 231–238. [PubMed]

50. Pauleau, A.L.; Rutschman, R.; Lang, R.; Pernis, A.; Watowich, S.S.; Murray, P.J. Enhancer-mediated control of 
    macrophage-specific arginase 1 expression. *J. Immunol.* **2004**, *172*, 7565–7573. [PubMed]

51. Lang, R.; Patel, D.; Morris, J.J.; Rutschman, R.L.; Murray, P.J. Shaping gene expression in activated and 
    resting primary macrophages by IL-10. *J. Immunol.* **2002**, *169*, 2253–2263. [CrossRef] [PubMed]

52. Gordon, S. Alternative activation of macrophages. *Nat. Rev. Immunol.* **2003**, *3*, 23–35. [CrossRef] [PubMed]

53. Xu, H.; Zhu, J.; Smith, S.; Foldi, J.; Zhao, B.; Chung, A.Y.; Outtz, H.; Kitajewski, J.; Shi, C.; Weber, S.; 
    et al. Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage 
    polarization. *Nat. Immunol.* **2012**, *13*, 642–650. [CrossRef] [PubMed]

54. Whyte, C.S.; Bishop, E.T.; Ruckerl, D.; Gaspar-Pereira, S.; Barker, R.N.; Allen, J.E.; Rees, A.J.; Wilson, H.M. 
    Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and 
    function. *J. Leukoc. Biol.* **2011**, *90*, 845–854. [CrossRef] [PubMed]

55. Liu, Y.; Stewart, K.N.; Bishop, E.; Marek, C.J.; Kluth, D.C.; Rees, A.J.; Wilson, H.M. Unique expression 
    of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro 
    and in vivo. *J. Immunol.* **2008**, *160*, 6270–6278. [CrossRef] [PubMed]

56. Wang, Y.C.; He, F.; Feng, F.; Liu, X.W.; Dong, G.Y.; Qin, H.Y.; Hu, X.B.; Zheng, M.H.; Liang, L.; Feng, L.; 
    et al. Notch signaling determines the M1 versus M2 polarization of macrophages in tumour antitumor 
    immune responses. *Cancer Res.* **2010**, *70*, 4840–4849. [CrossRef] [PubMed]

57. Odegaard, J.I.; Ricardo-Gonzalez, R.R.; Goforth, M.H.; Morel, C.R.; Subramanian, V.; Mukundan, L.; 
    Eagle, A.R.; Vats, D.; Brombacher, F.; Ferrante, A.W.; et al. Macrophage-specific ppargamma controls 
    alternative activation and improves insulin resistance. *Nature* **2007**, *447*, 1116–1120. [CrossRef] [PubMed]

58. Kang, K.; Reilly, S.M.; Karabacak, V.; Gangl, M.R.; Fitzgerald, K.; Hatano, B.; Lee, C.H. Adipocyte-derived 
    TH2 cytokines and myeloid ppardelta regulate macrophage polarization and insulin sensitivity. *Cell Metab.* 
    **2008**, *7*, 485–495. [CrossRef] [PubMed]

59. Liao, X.; Sharma, N.; Kapadia, F.; Zhou, G.; Lu, Y.; Hong, H.; Paruchuri, K.; Mahabeleshwar, G.H.; Dalmas, E.; 
    Venteclef, N.; et al. Kruppel-like factor 4 regulates macrophage polarization. *J. Clin. Investig.* **2011**, *121*, 
    2736–2749. [CrossRef] [PubMed]

60. Mahabeleshwar, G.H.; Kawanami, D.; Sharma, N.; Takami, Y.; Zhou, G.; Shi, H.; Naylor, L.; Jeyaraj, D.; 
    Grealy, R.; White, M.; et al. The myeloid transcription factor KLF2 regulates the host response to 
    polymicrobial infection and endotoxic shock. *Immunity* **2011**, *34*, 715–728. [CrossRef] [PubMed]

61. Pello, O.M.; De Pizzolo, M.; Mirolo, M.; Soucek, L.; Zammataro, L.; Amabile, A.; Doni, A.; Nebuloni, M.; 
    Swigart, L.B.; Evan, G.I.; et al. Role of c-MYC in alternative activation of human macrophages and 
    tumor-associated macrophage biology. *Blood* **2012**, *119*, 411–421. [CrossRef] [PubMed]

62. Hagemann, T.; Lawrence, T.; McNeish, I.; Charles, K.A.; Kulbe, H.; Thompson, R.G.; Robinson, S.C.; 
    Balkwill, F.R. “Re-educating” tumor-associated macrophages by targeting nf-kappab. *J. Exp. Med.* **2008**, *205*, 
    1261–1268. [CrossRef] [PubMed]

63. Han, M.S.; Jung, D.Y.; Morel, C.; Lakhani, S.A.; Kim, J.K.; Flavell, R.A.; Davis, R.J. JNK expression by 
    macrophages promotes obesity-induced insulin resistance and inflammation. *Science* **2013**, *339*, 218–222. 
    [CrossRef] [PubMed]

64. Takeda, N.; O’Dea, E.L.; Doedens, A.; Kim, J.W.; Weidemann, A.; Stockmann, C.; Asagiri, M.; Simon, M.C.; 
    Hoffmann, A.; Johnson, R.S. Differential activation and antagonistic function of hif-α isoforms in 
    macropages are essential for NO homeostasis. *Genes Dev.* **2010**, *24*, 491–501. [CrossRef] [PubMed]

65. Wu, X.Q.; Dai, Y.; Yang, Y.; Huang, C.; Meng, X.M.; Wu, B.M.; Li, J. Emerging role of microRNAs in regulating 
    macrophage activation and polarization in immune response and inflammation. *Immunology* **2016**, *148*, 
    237–248. [CrossRef] [PubMed]

66. Graff, J.W.; Dickson, A.M.; Clay, G.; McCaffrey, A.P.; Wilson, M.E. Identifying functional micrornas in 
    macropages with polarized phenotypes. *J. Biol. Chem.* **2012**, *287*, 21816–21825. [CrossRef] [PubMed]

67. Bilzer, M.; Roggel, F; Gerbes, A.L. Role of Kupffer cells in host defense and liver disease. *Liver Int.* **2006**, *26*, 
    1175–1186. [CrossRef] [PubMed]
68. Swirski, F.K.; Libby, P.; Aikawa, E.; Alcaide, P.; Luscinskas, F.W.; Weissleder, R.; Pittet, M.J. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheroma. J. Clin. Investig. 2007, 117, 195–205. [CrossRef] [PubMed]

69. Odegaard, J.I.; Chawla, A. Alternative macrophage activation and metabolism. Ann. Rev. Pathol. 2011, 6, 275–297. [CrossRef] [PubMed]

70. Duarte, N.; Coelho, I.C.; Patarrao, R.S.; Almeida, J.I.; Penha-Goncalves, C.; Macedo, M.P. How inflammation impinges on NAFLD: A role for Kupffer cells. BioMed Res. Int. 2015, 2015, 984578. [CrossRef] [PubMed]

71. Petrasek, J.; Bala, S.; Csak, T.; Lippai, D.; Kodys, K.; Menashy, V.; Barrieau, M.; Min, S.Y.; Kurt-Jones, E.A.; Szabo, G. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J. Clin. Investig. 2012, 122, 3476–3489. [CrossRef] [PubMed]

72. Tomiyama, K.; Ikeda, A.; Ueki, S.; Nakao, A.; Stolz, D.B.; Koike, Y.; Afrazi, A.; Gandhi, C.; Tokita, D.; Geller, D.A.; et al. Inhibition of Kupffer cell-mediated early proinflammatory response with carbon monoxide in transplant-induced hepatic ischemia/reperfusion injury in rats. Hepatology 2008, 48, 1608–1620. [CrossRef] [PubMed]

73. Liaskou, E.; Wilson, D.V.; Oo, Y.H. Innate immune cells in liver inflammation. Mediat. Inflamm. 2012, 2012, 949157. [CrossRef] [PubMed]

74. Tanti, J.F.; Jager, J. Cellular mechanisms of insulin resistance: Role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr. Opin. Pharmacol. 2009, 9, 753–762. [CrossRef] [PubMed]

75. Senn, J.J.; Klover, P.J.; Nowak, I.A.; Mooney, R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002, 51, 3391–3399. [CrossRef] [PubMed]

76. Olefsky, J.M.; Glass, C.K. Macrophages, inflammation, and insulin resistance. Ann. Rev. Physiol. 2010, 72, 219–246. [CrossRef] [PubMed]

77. Wick, G.; Grundtman, C.; Mayerl, C.; Wimpissinger, T.F.; Zelger, B.; Sgonc, R.; Wolfram, D.; et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: Implications for the pathogenesis of human nonalcoholic steatohepatitis. J. Clin. Investig. 2013, 123, 1887–1901. [CrossRef] [PubMed]

78. Wynn, T.A.; Barron, L. Macrophages: Master regulators of inflammation and fibrosis. Semin. Liver Dis. 2010, 30, 245–257. [CrossRef] [PubMed]

79. Takehara, T.; Tatsumi, T.; Suzuki, T.; Rucker, E.B., III; Hennighausen, L.; Jinushi, M.; Miyagi, T.; Kanazawa, Y.; Hayashi, N. Hepatocyte-specific disruption of BCL-XL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 2004, 127, 1189–1197. [CrossRef] [PubMed]

80. Otoh, S.; Kinosita, K.; Fujii, H.; Sakabe, M.; Shiga, R.; Nakatani, K.; Ikeda, K.; Nakajima, Y.; Ikura, Y.; Ueda, M.; et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: Implications for the pathogenesis of human nonalcoholic steatohepatitis. Am. J. Pathol. 2007, 167, 967–980. [CrossRef] [PubMed]

81. Patsenker, E.; Popov, Y.; Stickel, F.; Jonczyk, A.; Goodman, S.L.; Schuppan, D. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008, 135, 660–670. [CrossRef] [PubMed]

82. Lee, C.G.; Homer, R.J.; Zhu, Z.; Lanone, S.; Wang, X.; Koteliansky, V.; Shipley, J.M.; Gotwals, P.; Noble, P.; Chen, Q.; et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta1. J. Exp. Med. 2001, 194, 809–821. [CrossRef] [PubMed]

83. Karlmark, K.R.; Weiskirchen, R.; Zimmermann, H.W.; Gassler, N.; Ginhoux, F.; Weber, C.; Merad, M.; Luedde, T.; Trautwein, C.; Tacke, F. Hepatic recruitment of the inflammatory GRI+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009, 50, 261–274. [CrossRef] [PubMed]

84. Seki, E.; de Minicis, S.; Inokuchi, S.; Taura, K.; Miyai, K.; van Rooijen, N.; Schwabe, R.F.; Brenner, D.A. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009, 50, 185–197. [CrossRef] [PubMed]

85. Stanner, S.A.; Hughes, J.; Kelly, C.N.; Butttriss, J. A review of the epidemiological evidence for the ‘antioxidant hypothesis’. Public Health Nutr. 2004, 7, 407–422. [CrossRef] [PubMed]

86. Sugiyama, M.; Ogawa, K.; Yano, M. Comparison of bioavailability between beta-cryptoxanthin and beta-carotene and tissue distribution in its intact form in rats. Biosci. Biotechnol. Biochem. 2014, 78, 307–310. [CrossRef] [PubMed]
88. Yilmaz, B.; Sahin, K.; Bilen, H.; Bahcecioglu, I.H.; Bilir, B.; Ashraf, S.; Halazun, K.J.; Kucuk, O. Carotenoids and non-alcoholic fatty liver disease. *Hepatobiliary Surg. Nutr.* **2015**, *4*, 161–171. [PubMed]

89. Yadav, D.; Herten, H.I.; Schweitzer, P.; Norkus, E.P.; Pitchumoni, C.S. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis *C*. *Am. J. Gastroenterol.* **2002**, *97*, 2634–2639. [CrossRef] [PubMed]

90. Ruhl, C.E.; Everhart, J.E. Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. *Gastroenterology* **2003**, *124*, 1821–1829. [CrossRef]

91. Gunanti, I.R.; Marks, G.C.; Al-Mamun, A.; Long, K.Z. Low serum concentrations of carotenoids and vitamin C, vitamin E, and the carotenoids are influenced by diet, race and obesity in a sample of healthy adolescents. *J. Nutr.* **2001**, *131*, 2184–2191. [PubMed]

92. Garcia, O.P.; Long, K.Z.; Rosado, J.L. Impact of micronutrient deficiencies on obesity. *Nutr. Rev.* **2009**, *67*, 559–572. [CrossRef] [PubMed]

93. Neuhouser, M.L.; Rock, C.L.; Eldridge, A.L.; Kristal, A.R.; Patterson, R.E.; Cooper, D.A.; Neumark-Sztainer, D.; Cheskin, L.J.; Thornequist, M.D. Serum concentrations of retinol, alpha-tocopherol and the carotenoids are influenced by diet, race, and obesity in a sample of healthy adolescents. *J. Nutr.* **2001**, *131*, 1462–1469. [CrossRef] [PubMed]

94. Cao, Y.; Wang, C.; Liu, J.; Liu, Z.M.; Ling, W.H.; Chen, Y.M. Greater serum carotenoid levels associated with lower prevalence of nonalcoholic fatty liver disease in Chinese adults. *Sci. Rep.* **2015**, *5*, 12951. [CrossRef] [PubMed]

95. Sugiura, M.; Nakamura, M.; Ogawa, K.; Ikoma, Y.; Yano, M. High serum carotenoids are associated with lower risk for developing elevated serum alanine aminotransferase among Japanese subjects: The mikkabi cohort study. *Br. J. Nutr.* **2016**, *115*, 1462–1469. [CrossRef] [PubMed]

96. Al-Busafi, S.A.; Bhat, M.; Wong, P.; Ghali, P.; Deschenes, M. Antioxidant therapy in nonalcoholic steatohepatitis. *Hepat. Res. Treat.* **2012**, *2012*, 947575. [CrossRef] [PubMed]

97. Chung, M.Y.; Yeung, S.F.; Park, H.J.; Volek, J.S.; Bruno, R.S. Dietary alpha- and gamma-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis. *J. Nutr. Biochem.* **2010**, *21*, 1200–1206. [CrossRef] [PubMed]

98. Nan, Y.M.; Wu, W.J.; Fu, N.; Liang, B.L.; Wang, R.Q.; Li, L.X.; Zhao, S.X.; Zhao, J.M.; Yu, J. Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice. *Scand. J. Gastroenterol.* **2009**, *44*, 1121–1131. [PubMed]

99. Rock, C.L.; Jacob, R.A.; Bowen, P.E. Update on the biological characteristics of the antioxidant micronutrients: vitamin C, vitamin E, and the carotenoids. *J. Am. Diet. Assoc.* **1996**, *96*, 693–702. [CrossRef]

100. Kaulmann, A.; Bohn, T. Carotenoids, inflammation, and oxidative stress—Implications of cellular signaling pathways and relation to chronic disease prevention. *Nutr. Res.* **2014**, *34*, 907–929. [CrossRef] [PubMed]

101. Ni, Y.; Nagashimada, M.; Zhan, L.; Nagata, N.; Kobori, M.; Sugiuira, M.; Ogawa, K.; Ikoma, Y.; Yan, M. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, beta-cryptoxanthin. *Endocrinology* **2015**, *156*, 987–999. [CrossRef] [PubMed]

102. Ni, Y.; Nagashimada, M.; Zhuge, F.; Zhan, L.; Nagata, N.; Tsutsui, A.; Nakamura, Y.; Kaneko, S.; Ota, T. Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E. *Sci. Rep.* **2015**, *5*, 17192. [CrossRef] [PubMed]

103. Sugiuira, M.; Nakamura, M.; Ogawa, K.; Ikoma, Y.; Matsumoto, H.; Ando, F.; Shimokata, H.; Yano, M. Synergistic interaction of cigarette smoking and alcohol drinking with serum carotenoid concentrations: Findings from a middle-aged Japanese population. *Br. J. Nutr.* **2009**, *102*, 1211–1219. [CrossRef] [PubMed]

104. Sugiuira, M.; Nakamura, M.; Ikoma, Y.; Yano, M.; Ogawa, K.; Matsumoto, H.; Kato, M.; Ohshima, M.; Nagao, A. The homeostasis model assessment-insulin resistance index is inversely associated with serum carotenoids in non-diabetic subjects. *J. Epidemiol. Jpn. Epidemiol. Assoc.* **2006**, *16*, 71–78. [CrossRef]

105. Sugiuira, M.; Nakamura, M.; Ikoma, Y.; Yano, M.; Ogawa, K.; Matsumoto, H.; Kato, M.; Ohshima, M.; Nagao, A. High serum carotenoids are inversely associated with serum gamma-glutamyltransferase in alcohol drinkers within normal liver function. *J. Epidemiol. Jpn. Epidemiol. Assoc.* **2005**, *15*, 180–186. [CrossRef]

106. Lorenzo, Y.; Azqueta, A.; Luna, L.; Bonilla, F.; Dominguez, G.; Collins, A.R. The carotenoid beta-cryptoxanthin stimulates the repair of DNA oxidation damage in addition to acting as an antioxidant in human cells. *Carcinogenesis* **2009**, *30*, 308–314. [CrossRef] [PubMed]

107. Unno, K.; Sugiuira, M.; Ogawa, K.; Takabayashi, F.; Toda, M.; Sakuma, M.; Maeda, K.; Fujitani, K.; Miyazaki, H.; Yamamoto, H.; et al. Beta-cryptoxanthin, plentiful in Japanese mandarin orange, prevents
age-related cognitive dysfunction and oxidative damage in senescence-accelerated mouse brain. *Biol. Pharm. Bull.* **2011**, *34*, 311–317. [CrossRef] [PubMed]

108. Haegele, A.D.; Gillette, C.; O’Neill, C.; Wolfe, P.; Heimendinger, J.; Sedlacek, S.; Thompson, H.J. Plasma xanthophyll carotenoids correlate inversely with indices of oxidative DNA damage and lipid peroxidation. *Cancer Epidemiol. Biomark. Prev.* **2000**, *9*, 421–425.

109. Matsumoto, C.; Ashida, N.; Yokoyama, S.; Tominari, T.; Hirata, M.; Ogawa, K.; Sugiura, M.; Yano, M.; Inada, M.; Miyaura, C. The protective effects of beta-cryptoxanthin on inflammatory bone resorption in a mouse experimental model of periodontitis. *Biosci. Biotechnol. Biochem.* **2013**, *77*, 860–862. [CrossRef] [PubMed]

110. Katsuura, S.; Imamura, T.; Bando, N.; Yamanishi, R. Beta-carotene and beta-cryptoxanthin but not lutein evoke redox and immune changes in raw264 murine macrophages. *Mol. Nutr. Food Res.* **2009**, *53*, 1396–1405. [CrossRef] [PubMed]

111. Kobori, M.; Ni, Y.; Takahashi, Y.; Watanabe, N.; Sugiura, M.; Ogawa, K.; Nagashimada, M.; Kaneko, S.; Naito, S.; Ota, T. Beta-cryptoxanthin alleviates diet-induced nonalcoholic steatohepatitis by suppressing inflammatory gene expression in mice. *PLoS ONE* **2014**, *9*, e98294. [CrossRef] [PubMed]

112. Ambati, R.R.; Phang, S.M.; Ravi, S.; Aswathanarayana, R.G. Astaxanthin: Sources, extraction, stability, biological activities and its commercial applications—A review. *Mar. Drugs* **2014**, *12*, 128–152. [CrossRef] [PubMed]

113. Guerin, M.; Huntley, M.E.; Olaizola, M. Haematococcus astaxanthin: Applications for human health and nutrition. *Trends Biotechnol.* **2003**, *21*, 210–216. [CrossRef]

114. Yuan, J.P.; Peng, J.; Yin, K.; Wang, J.H. Potential health-promoting effects of astaxanthin: A high-value carotenoid mostly from microalgae. *Mol. Nutr. Food Res.* **2011**, *55*, 150–165. [CrossRef] [PubMed]

115. Kang, J.O.; Kim, S.J.; Kim, H. Effect of astaxanthin on the hepatotoxicity, lipid peroxidation and antioxidantive enzymes in the liver of CCl4-treated rats. *Methods Find. Exp. Clin. Pharmacol.* **2001**, *23*, 79–84. [CrossRef] [PubMed]

116. Jornayvaz, F.R.; Jurczak, M.J.; Lee, H.Y.; Birkenfeld, A.L.; Frederick, D.W.; Zhang, D.; Zhang, X.M.; Samuel, V.T.; Shulman, G.I. A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. *Am. J. Physiol. Endocrinol. Metab.* **2010**, *299*, E808–E815. [CrossRef] [PubMed]

117. Ikeuchi, M.; Koyama, T.; Takahashi, J.; Yazawa, K. Effects of astaxanthin in obese mice fed a high-fat diet. *Biosci. Biotechnol. Biochem.* **2007**, *71*, 893–899. [CrossRef] [PubMed]

118. Yang, Y.; Kim, B.; Park, Y.K.; Koo, S.I.; Lee, J.Y. Astaxanthin prevents TGFbeta1-induced pro-fibrogenic gene expression by inhibiting Smad3 activation in hepatic stellate cells. *Biochim. Biophys. Acta* **2015**, *1850*, 178–185. [CrossRef] [PubMed]

119. Yang, Y.; Bae, M.; Kim, B.; Park, Y.K.; Koo, S.I.; Lee, J.Y. Astaxanthin prevents and reverses the activation of mouse primary hepatic stellate cells. *J. Nutr. Biochem.* **2016**, *29*, 21–26. [CrossRef] [PubMed]

120. Ishiki, M.; Nishida, Y.; Ishibashi, H.; Wada, T.; Fujisaka, S.; Takikawa, A.; Urakaze, M.; Sasaoka, T.; Usui, I.; Tobe, K. Impact of divergent effects of astaxanthin on insulin signaling in l6 cells. *Endocrinology* **2013**, *154*, 2600–2612. [CrossRef] [PubMed]

121. Wang, Y.; Ausman, L.M.; Greenberg, A.S.; Russell, R.M.; Wang, X.D. Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis-promoted hepatocarcinogenesis in rats. *Int. J. Cancer* **2010**, *126*, 1788–1796. [CrossRef] [PubMed]

122. Bahcecioglu, I.H.; Kuzu, N.; Metin, K.; Ozercan, I.H.; Ustundag, B.; Sahin, K.; Kucuk, O. Lycopene prevents development of steatohepatitis in experimental nonalcoholic steatohepatitis model induced by high-fat diet. *Vet. Med. Int.* **2010**, *2010*. [CrossRef] [PubMed]

123. Erhardt, A.; Stahl, W.; Sies, H.; Lirussi, F.; Donner, A.; Haussinger, D. Plasma levels of vitamin e and carotenoids are decreased in patients with nonalcoholic steatohepatitis (NASH). *Eur. J. Med. Res.* **2011**, *16*, 76–78. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).